Evidence map›Paper›PMID 41828722›Full record

ArticleInternational journal of molecular sciences2026

Pregnanolone Glutamate: A Dual-Fate Delivery System for Neuroactive Steroids in Perinatal Focal Cerebral Ischemia.

Grygoriy Tsenov, Iqra Bano, Marta Velíková, Viera Kútna, Hana Chodounská, Eva Kudová, Josef Bulant, Martin Hill

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grygoriy TsenovPreclinical Research Program, Division of Experimental Neurobiology, National Institute of Mental Health, 250 67 Klecany, Czech Republic.
Iqra BanoPreclinical Research Program, Division of Experimental Neurobiology, National Institute of Mental Health, 250 67 Klecany, Czech Republic.ORCID 0000-0003-0189-3261
Marta VelíkováInstitute of Endocrinology, 110 00 Prague, Czech Republic.
Viera KútnaPreclinical Research Program, Division of Experimental Neurobiology, National Institute of Mental Health, 250 67 Klecany, Czech Republic.
Hana ChodounskáInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 160 00 Prague, Czech Republic.
Eva KudováInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, 160 00 Prague, Czech Republic.ORCID 0000-0001-7131-5948
Josef BulantInstitute of Endocrinology, 110 00 Prague, Czech Republic.
Martin HillInstitute of Endocrinology, 110 00 Prague, Czech Republic.ORCID 0000-0002-1705-0835

Funding

Academy of Sciences of the Czech Republic grant RVO 61388963Czech Science Foundation (GAČR) 23-05746SEuropean Regional Development Fund-Project "PharmaBrain" No. CZ.02.1.01/0.0/0.0/16_025/0007444.Ministry of Health of the Czech Republic MH CZ-DRO (Institute of Endocrinology, 00023761)
6 · The paper itself

Abstract

Pregnanolone glutamate (PG) is a synthetic neurosteroid analog showing promise for treating ischemic brain injury, yet its blood-brain barrier (BBB) transport and metabolic fate remain unclear. We investigated the pharmacokinetics of PG in postnatal day 12 rats of both sexes subjected to endothelin-1 (ET-1)-induced focal hippocampal ischemia. Animals received PG (1 mg/kg intraperitoneal (i.p.)) or vehicle; serum and hippocampal steroidomes were profiled 60 min post-administration using gas chromatography-tandem mass spectrometry (GC-MS/MS) (hippocampus: n = 16 PG+, n = 27 PG-; multi-tissue subset: n = 6 PG+, n = 21 PG-). Our data revealed a "dual-fate" mechanism: PG undergoes systemic hydrolysis as a prodrug, as suggested by the tissue distribution pattern at 60 min post-administration, but also crosses the BBB intact, with significant parent conjugate accumulation in the hippocampus (42.3 pmol/g). The brain functioned as a "metabolic sink", passively accumulating metabolites generated in peripheral organs-such as 17-hydroxypregnanolone-despite local absence of synthesizing enzymes (e.g., CYP17A1). Crucially, PG induced "metabolic segregation" within the central nervous system (CNS): the pharmacological 5β-pathway was saturated (~170-fold pregnanolone increase), while endogenous neuroprotective 5α-pathway (allopregnanolone) homeostasis remained preserved, contrasting with peripheral metabolic saturation. Preferential hippocampal accumulation of 3-oxo and 3β-isomers suggests autonomous regulatory buffering via oxidative 17β-hydroxysteroid dehydrogenase (HSD17B) enzymes, protecting against excessive GABAergic inhibition. This unique pharmacokinetic profile-combining metabolic segregation with active central buffering-defines PG as a dual-mechanism delivery system that generates central neuroactive metabolites-several with previously established GABAergic and neuroprotective activity-without disrupting endogenous neurosteroidogenesis, positioning it as a promising neurotherapeutic candidate minimizing physiological steroid homeostasis disruption. Importantly, the present study characterizes the pharmacokinetic and metabolic fate of PG; the neuroprotective efficacy of PG was demonstrated in our prior functional studies using the same model.

Indexed as

Brain IschemiaNeurosteroidsPregnanoloneAnimalsBlood-Brain BarrierFemaleHippocampusMaleRatsNeurosteroidsPregnanoloneblood-brain barrierGC-MS/MSmetabolic segregationneuroactive steroidsneuroprotectionpharmacokineticspregnanolone glutamatesteroidome

Identifiers

PMID41828722
PMCPMC12985710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.